Physician profile
Marc B Garnick
NPI 1861429342
$139,397.78
in general payments reported to CMS, 2019-2025
8 companies · $27K in 2025
The $27K reported for 2025 was more than what 94% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $15K · 2021: $18K · 2022: $12K · 2023: $27K · 2024: $14K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $68K · Food and Beverage: $205 · Travel and Lodging: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $68,317.50 |
| Food and Beverage | $205.02 |
| Travel and Lodging | $100.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $63,781.25 | 2020-2025 | Jemperli |
| Incyte Corporation | $15,000.00 | 2021 | |
| Janssen Research & Development, LLC | $13,500.00 | 2024 | Carvykti |
| Eli Lilly and Company | $12,901.37 | 2019 | |
| Amag Pharmaceuticals, INC. | $10,769.43 | 2019 | |
| Acrotech Biopharma INC. | $10,725.00 | 2023 | Beleodaq |
| Janssen Scientific Affairs, LLC | $9,470.73 | 2019-2024 | Erleada |
| Tolmar Pharmaceuticals, INC. | $3,250.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Garnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.